UrgoStart Border Logo
Also available as a contact layer : click here
Also available as a foam : click here

Highly absorbent dressing with protease inhibitor (unique TLC-NOSF matrix), silicone border and waterproof backing for treating moderately to heavily exuding chronic wounds.



UrgoStart Border pack

100 days label

 UrgoStart gives you the power to reduce healing time for your patients by 100 days (1)

  • - With all the benefits of the TLC Healing Matrix: pain-free dressing changes (2,3,4,5,6), moist wound-healing (2,7), good tolerance (8), stimulation of fibroblast proliferation (9,10)
  • - Highly absorbent dressing with protease inhibitor, silicone border and waterproof backing for healing moderately to heavily exuding chronic wounds
  • - TLC-NOSF clinically proven in a double blind Randomised Controlled Trial (8)



  • Moderate to heavily exuding chronic wounds (leg ulcers, pressure ulcers, diabetic foot ulcers) or longstanding acute wounds
  • The earlier UrgoStart is initiated, the shorter time to wound closure
  • For best results use for a recommended treatment duration of 12 weeks
  • May be left in place for up to 7 days


Precautions for use and Contra-Indications

  • Do not use on infected or critically colonised wounds
  • Do not use in cancerous wounds and fistula wounds which may reveal a deep abcess
  • In the absence of clinical data as a first line treatment in acute wounds, and in the treatment of EB, it is not recommended to use Urgostart Border.
  • Do not use in a hyperbaric chamber
  • Do not use if there is a known sensitivity to the dressing 



(1) Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. Journal of Wound Care 2017; 26: WUWHS Suppl, S4–S15.

(2) Benbow M., Iossen G. A clinical evaluation of UrgoTul to treat acute and chronic wounds. Br J Nurs 2004: 13 (2): 105-109.

(3) Meaume S. et al. Optimizing wound care with a new lipido-colloid dressing (UrgoTul Duo) Br J Nurs 2007: 16 (6): S4-12.

(4) Smith J. et al. Evaluation of UrgoTul plus K-four compression for venous leg ulcers, Br J Nurs 2004: 13 (6): S20-28.

(5 )Fays S. et al. Leg ulcers and the UrgoCell Non-Adhesive wound dressing. Br J Nurs 2005: 14 (11):S15-20.

(6) UrgoCell® Start TLC/UrgoCell® TLC. Data on file, 2009. Urgo.

(7) Winter G.D. Formation of the scab and rate of epithelialisation of superficial wounds in the skin of the young domestic pig.
Nature 1962; 193: 293-294.

(8) Meaume S. et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-Oligo
Saccharide Factor wound dressing in the local management of venous leg ulcers. ; Wound Rep Reg. 2012 (July/ August) vol 20
issue 4, p 500-511

(9) Bernard F.X. et al. Stimulation of the proliferation of human dermal fibroblasts in vitro by a lipido-colloid dressing J Wound Care
2005; 14 (5): 215-220.

(10) UrgoStart®, UrgoStart® Contact. Data on file. 2011. Urgo.